HPV and cervical cancer were used interchangeably by some, and the connection in both girls’ and parents’ minds was tenuous. More often than not, participants offered that they were not sure what the difference was between the two. When girls were asked what the vaccination was called, responses varied from “The Cervix Needle” (F, FG2) to “The Vagina Cancer” (E, FG1). “I think they are pretty much the same cancer [HPV and cervical cancer], but in different places… Like you can get like brain cancer, skin cancer, so it’s in different sections of your body…” (H, FG1). Parents were also confused about the HPV and cervical cancer relationship,

often misusing names. When asked what HPV was, one parent responded “I don’t know what

it stands for. It’s a vaccination for cervical http://www.selleckchem.com/products/LY294002.html cancer” (F, P1). A second theme that described lack of knowledge was knowledge about HPV vaccination. Lack of understanding of vaccination was evident throughout many sub-categories, including what the vaccine protects against, how the vaccine works, HPV vaccination recommendations, the vaccine and Pap smear connection, and myths about HPV vaccination. Girls and parents were confused about what the HPV vaccine protected the girls against, though girls seemed more confused than parents. A majority of individuals thought that they selleck were now completely protected against cervical cancer. One girl stated, “From what I’ve heard, I feel like I can’t get it [cervical cancer] at all now” (J, FG2). A parent discussed why there might be so much why confusion about this: “…just the adverts on TV. It just brought across the idea to most people that this is the thing that is going to stop you getting cervical cancer” (B, P2). Some girls also mentioned that they might be protected from other sexually transmitted infections and pregnancy, though genital warts were not mentioned. After being asked what the vaccine prevented, the girls

in one focus group answered: “STDs I guess…” and another girl followed with “Not only that particular one [HPV]…” and another surmised, “[The vaccine is] Not for all sexually transmitted diseases, but only one type I’d guess…” (A, FG1). The way that the vaccine works was also a mystery to the participants who were interviewed. “Me and my mum looked over the booklet that was given and it said it only helps to prevent four HPV diseases and there’s a hundred or more, so it doesn’t seem very effective…” (F, FG1). Many parents and girls mistook the virus-like particles in the vaccine for the HPV virus or cancer. Other participants had some general ideas about how vaccinations worked, and applied that knowledge to the current vaccine. However, the idea that cancer was given as part of the vaccine was also prominent. “I thought that in the cancer needle when you got it they have a bit of cancer in it so your body can learn to fight it.

Each belief was multiplied by the corresponding motivation INCB024360 to comply [19] and a mean computed. Control beliefs were assessed by 14 items. Each belief was multiplied by the corresponding power item [19] and a mean computed. Table 4 summarises differences between MMR and dTaP/IPV in terms of parents’ scores on each TPB component. The descriptive statistics indicate that most parents intended to immunise, and most had reasonably positive attitudes towards immunising, moderately strong subjective norms and high perceived control. Belief composites are discussed in 3.7. There was no significant

difference between the two vaccinations on any of the TPB components (p > 0.05). As scores for intention were severely skewed, an inverse transformation was conducted [20], but this did not render the distribution normal. Inhibitor Library high throughput Thus, intention was dichotomised into parents with ‘maximum immunisation intentions’ (MI; maximum possible score of +3) and parents with ‘less than maximum intentions’ (LMI; score <3). Of the 147 parents in the MMR group, 65 (44.2%) had maximum intentions and 82 (55.8%) less than maximum intentions. Of the 108 parents in the dTaP/IPV group, 57 (52.8%) had maximum intentions and 51 (47.2%) had less than maximum intentions. There was no relationship between intention (MI;

LMI) and vaccination (MMR; dTaP/IPV): 2 × 2 χ2(1, n = 255) = 1.828, p = 0.176. Biserial correlation coefficients (rb) were computed between dichotomised intention (MI;

LMI) and the TPB components. Spearman’s correlation coefficients (rs) were computed between the TPB components and sociodemographic variables for MMR ( Table 5) and dTaP/IPV ( Table 6) separately. When interpreting the biserial correlation coefficients (rb), information about the direction of the relationship should be ignored, as the sign of the coefficient is dependent on how the category (intention) is coded [24]. With a Bonferroni correction to overcome the likelihood of a Type 1 error (0.05 divided by 45), only differences p ≤ 0.001 were considered significant [24]. For MMR, all TPB components (the three direct predictors and three belief composites) correlated significantly to with intention. For dTaP/IPV, all TPB components were significantly correlated with intention, except for subjective norm, normative beliefs and control beliefs (p > 0.001). Of the sociodemographic variables, number of children correlated significantly with intention to immunise with dTaP/IPV. For both vaccinations, each belief composite correlated significantly with its direct predictor of intentions (i.e. behavioural beliefs correlated with attitudes). Among the three direct predictors from the TPB, attitude correlated most strongly with intention. The relationship between each of the remaining sociodemographic variables and dichotomised intention were examined using Pearson’s chi-square tests for MMR and dTaP/IPV separately.

MMC and EMC showed antibacterial activity against S. aureus (28 mm, 15 mm), B. subtilis (23 mm, 20 mm), K. pneumonia (12 mm, 15 mm), P. vulgaris (22 mm, 27 mm) and E. coli (28 mm, 20 mm) at 100 μg concentration itself and increased activity with increasing concentrations. 5-FU research buy This effect was concentration-dependent. It doesn’t produce any effect in 50 μg, whereas, both the extracts do not inhibit the fungi, A. niger and C. albicans. The present study involved in pharmacognostical characterization of M. cochinchinensis seeds to confirm the taxa and to avoid the substitutes in indigenous medicinal preparations. The

staining results were remarkably good and some cytochemical reactions were also obtained. Comparative anatomical studies on seeds of Mucuna Adans and Canavalia DC. species were studied and resolved that the features such as rim-aril, cuticle, palisade layer of osteosclereids, macrosclereids, selleck screening library hour glass cells, mesophylls and tracheid – bar of M. pruriens and other six species are common, but anatomical structures at hilar region seems to be important for diagnostic purpose. 9 Our results coincides the characterization results described earlier and thereby confirmed the species selected. Disc diffusion methods are used extensively to investigate the antibacterial activity of natural substances and plant extracts. Antibacterial

property of methanolic seed extracts of M. pruriens has been very well demonstrated. 10 and 11 Methanol extract of leaf of M. pruriens shows strong antibacterial activity against S. aureus, B. subtilis, E. coli and P. aeruginosa. 12 In this study MMC and EMC produced remarkable

antibacterial efficacy when compared with standard drug Chloramphenicol. Phytochemical analysis revealed the presence of flavonoids in both the extracts. Flavonoids not have been used extensively since centuries for the treatment of various diseases. 13 Quercetin, naringenin are reported to inhibit B. subtilis, C. albicans, E. coli, Staphylococcus nervous, Staphylococcus epidermis and Saccharomyces cerevisiae. 14Psidium guajava leaves are reported to have morin-3-O-lyxoside, morin-3-O-arabinoside, quercetin, quercetin-3-O-arabinoside and all these four possess bacteriostatic action against all food borne pathogenic bacteria including Bacillus stearothermophilus, Brochothrix thermosphacta, E. coli, Listeria monocytogenes, Pseudomonas fluorescens, Salmonella enteric, S. aureus, Vibrio cholera. 15 Flavonones having sugar moiety also exhibit potent antimicrobial activity. 16 The activity demonstrated here may be due to the presence of flavonoids in MMC and EMC. The pharmacognostic investigation shows that authentic botany of this crude drug prevents adulteration, substitution and has a crucial role in standardization of crude drugs. The preliminary phytochemical screening of the seeds of M. cochinchinensis indicates the presence of secondary metabolites, having an essential role in medicine.

5–7.5 median tissue culture infectious doses (TCID50) or fluorescent focus units of each of the 3 influenza strains (A/H1N1, A/H3N2, and B). Placebo Selleckchem Alisertib did not differ in appearance, delivery, or taste. In one study, 2 different placebo formulations (saline and excipient) were investigated; for this meta-analysis, as in the original study, data from these 2 groups were combined [12]. TIV-controlled trials used commercially-available

TIV approved for use in the corresponding region; children 6 months to younger than 36 months received 0.25 mL per dose (7.5 μg of each hemagglutinin) while children 36 months and older received 0.5 mL per dose (15 μg of each hemagglutinin). For the trials in which children received 2 doses, the time between doses was approximately

1 month, with the exception of one study in which the interval was 6–10 weeks [9] and [11]. Culture-confirmed symptomatic influenza illness was defined by a positive viral culture of a wild-type influenza virus. Nasal swab cultures PI3K Inhibitor Library ic50 were collected if a child had (1) ≥1 of the following: acute otitis media (suspected or diagnosed), fever, pneumonia, pulmonary congestion, shortness of breath, or wheezing or (2) ≥2 of the following symptoms concurrently: chills, cough, decreased activity, headache, irritability, muscle aches, pharyngitis, rhinorrhea, or vomiting. Criteria for obtaining a culture were generally consistent across trials, with the exception of slight variations in the definition of fever (minimum of ≥37.5 °C axillary, ≥38 °C oral, rectal, or tympanic), the start of surveillance after receiving the first dose (from 11 to 15 days or a specified date), and the recommended time between the onset of symptoms and collection of culture (from 24 h to 4 days) [19]. In all trials, central laboratories evaluated nasal swabs for the presence of influenza virus and subtypes, and serotypes were identified through antigenic methods. Subject-level data were extracted for eligible children from the clinical trial databases for each relevant study (Table 1). The data were analyzed using the SAS System for Windows version 8.2 (Cary, NC, USA). The meta-analysis

was conducted on the per-protocol Rutecarpine population using the fixed-effects model [21]. A log binomial model was used to calculate LAIV relative risk adjusting for study variation. LAIV efficacy relative to placebo and TIV was calculated as 1 minus the adjusted relative risk (RR) of culture-confirmed influenza in LAIV recipients relative to placebo or TIV recipients, respectively. The 95% CI of LAIV efficacy was constructed from the 95% CI of the adjusted RR. The Cochran Q statistic was used to assess the heterogeneity of the effects across trials [22]. Studies with no influenza cases for a particular subtype were excluded from the corresponding analysis. The 8 trials included 4288 children 24–71 months of age in placebo-controlled trials and 7986 children 24 months to 17 years of age in TIV-controlled trials (Table 1).

2 as a dissolution medium. At predetermined interval, the filtrate was analyzed by UV-spectrophotometer (λ = 335 nm). The loose and

tapped bulk densities of RAM, NIF and other excipients were determined by using a density apparatus (Serwell, India). The Compressibility index (CI %) and the Hausner’s ratio (HR) were calculated. Drug-excipients compatibility was carried out by FTIR spectroscopy and DSC. FTIR spectra of drugs and excipients were taken by using KBr pellet technique using a Shimadzu FT-IR spectrophotometer (Japan) in the wavelength region selleck of 4000 to 400 cm−1. Thermal analysis of samples (drug or mixture of drug/s and excipients) were carried out using DSC (Perkin–Elmer, USA) method with a heating rate of 10 °C/min from 0 to 300 °C.7 The composition of the tablets is shown in Table 1. The core tablets containing RAM and HPMC in IPA (T1–T3) were prepared by granulation and later mixed with avicel. Magnesium stearate and Ac-Di-Sol were added to each blend and further mixed. The resultant blends were tableted to 80 mg using 10 stations Cadmach tablet press (India). Enteric

coating was given with Eudragit 10% solution using a Gans coater (India) and the coating solution was applied till 2% weight gain was achieved (tablet weight: 90 mg). All materials such as NIF-loaded microcapsules and excipients were passed through sieve no. 80. The outer tablets containing microcapsules of NIF, starch, SSG and avicel were prepared by granulation. Magnesium stearate and aerosil were added to each blend and further mixed. The resultant blends were tableted keeping Mephenoxalone the core tablet in between to 450 mg

ABT-263 solubility dmso (core: 90 mg + outer: 360 mg) using a 10 stations Cadmach tablet press. Thickness of tablets (n = 3) was determined using Vernier caliper (Mitutoyo, Japan). USP stated weight variation test of the tablets (n = 20) was carried out using electronic balance (Shimadzu, Japan). The hardness of tablets (n = 5) was tested using Monsanto hardness tester (Electrolab, USA). For each formulation, the friability of 6 tablets was determined using the Friabilator (Electrolab, USA). For determining the drug content of core tablets, 20 tablets (n = 3) were crushed and 100 mg of powder was dissolved in 100 ml of HCl buffer pH 1.2 for outer tablet and phosphate buffer pH 6.8 for core tablet respectively. These filtered solutions were analyzed by UV-spectrophotometer at 335 nm and 210 nm for NIF and RAM respectively. Disintegration tests were performed on tablets as per USP using disintegration apparatus (Electrolab, USA). To ensure the quality of core centration of tab-in-tab formulations, longitudinal and the transverse cuts were executed as shown in Fig. 1. Once several tablets have been cut which measured various displacement quantities.8 The in-vitro dissolution study was carried out using a USP Type II dissolution apparatus (Electrolab, USA) in 900 ml of SGF pH 1.2 for the first 2 h, followed by 900 ml of pH 6.

When the length of the dissected ureter was shorter than the surgeon expected, the location of the ureterostoma could be easily moved to any place that was ideal for managing postoperative stoma care. To relieve an advanced pelvic cancer patient’s severe urinary-related pain, retroperitoneoscopic right cutaneous ureterostomy

followed by embolization of the left renal artery to eliminate left kidney function was performed. The patient was free from the painful urinary-related symptoms until he died of progressive disease. This treatment strategy is feasible for selected patients to avoid decreasing the quality of their remaining life. None of the authors have any potential conflicts of interest Protein Tyrosine Kinase inhibitor to declare. “
“Angiomyolipoma (AML) is a benign renal mesenchymal tumor affecting more than 10 million people worldwide, predominantly in women aged 40-50 buy Epacadostat years. It might be sporadic or occurs in association with tuberous sclerosis complex or lymphangioleiomyomatosis (LAM).1 There are 2 variants of AML: classic (triphasic) and epithelioid. Although AML is classically benign, the epithelioid variant can closely mimic renal cell carcinoma radiographically. Epithelioid AML has been reported to exhibit aggressive clinical course

with metastases, recurrences, and high rate of mortality.2, 3 and 4 Rarely, AML might invade the major renal vein and/or lymph nodes. However, involvement of regional lymph nodes is interpreted as multifocality of growth rather than true metastases or malignant

behavior. Herein, we report a case of lipomatous AML that demonstrates an unusual aggressive behavior with inferior vena cava (IVC) tumor thrombus. The patient is a 42-year-old asymptomatic woman with no past medical history referred to us on account of a hyperechoic right kidney mass and IVC thrombus found on routine abdominal ultrasound. Physical examination was unremarkable, and laboratory values were within normal limits, with hemoglobin of 13.2 g/dL and creatinine of 0.85 mg/dL. Computed tomographic (CT) scan of the abdomen confirmed a 3-cm right upper below pole renal mass with central fat attenuation and a 5-cm level II IVC thrombus (extension into the right renal vein and IVC below the level of the hepatic veins; Fig. 1A and B). Shortly after imaging diagnosis, she presented with a 1-week history of pleuritic chest pain and shortness of breath in the recumbent position. Urgent chest CT angiogram showed a pulmonary tumor embolus (−65 HU) in the right anterior segmental branch of the pulmonary artery, with a corresponding infarct in the medial segment of the right lower lung lobe. The CT also revealed multiple bilateral lung cysts, suggesting a diagnosis of LAM. She underwent a right radical nephrectomy and IVC thrombectomy through a modified Chevron incision.

The stepwise entry of variables in the model and continuation in the final model were determined by their relevance and AZD9291 datasheet statistical significance (p < 0.20 and p < 0.05, respectively). This study was approved by the Ethics in Research

Committees of the National School of Public Health-Fiocruz (document 236A/03 CEP-FIOCRUZ), and the Ministry of Health of the Federal District (Document SES-DF CEP-069/2005) authorized by ANVISA and registered in the International Standard Randomised Controlled Trial Number Register (ISRCTN 72367932). From a total of 1943 children, 115 in one health center were disregarded in the analysis because of inconsistencies in identification numbers of blood samples. All the remaining 1828 children received the MMR (Bio-Manguinhos/GSK, 48.5%, Merck, 35.6%, not recorded, 15.9%) and 59 (3.2%) did not receive yellow fever vaccine in the study. In the intention-to-treat analysis, SCH772984 ic50 we included the 1769 children who received yellow fever vaccine, and were thus randomly assigned to one type of YFV. Among those, 22 (1.2%) did not return for blood sampling after vaccination. Of those who returned, 43 (2.5%), 54 (3.1%), 56 (3.2%) and 24 (1.4%) did not have post-vaccination

serological status for rubella, measles, mumps and yellow fever, respectively (Fig. 1). The total loss was 13.5% and included subjects who did not return for vaccination or blood collection, or whose specimens were lost or were insufficient to perform the serological tests. These losses were not selective regarding study groups. Six children assigned to vaccination with an interval of 30 days received the vaccines simultaneously, whereas in 5 children the opposite occurred. The 59 volunteers first lost between the two randomization procedures were similar to those volunteers randomized to the vaccine against yellow fever, according to gender, age weight, and the proportion seropositive for rubella and yellow fever (Table 1). The base-line characteristics were well-balanced across comparison groups (Table 1). The proportion of children seropositive

to yellow fever before vaccination was substantially higher than for measles, mumps and rubella. The proportion of seroconversion and magnitude of immune response (GMT and distribution of postvaccination antibody titers) for rubella were substantially higher in the group in which YFV and MMR were given 30 days apart, compared to those vaccinated simultaneously (p < 0.001, Table 2 and Fig. 2). In contrast, the groups defined by the types of yellow fever vaccines showed no significant differences in immune response (p > 0.5, Table 2 and Fig. 2). In the logistic model for seroconversion only the interval between vaccines showed a statistically significant association (OR = 3.80, 95% CI: 2.39–6.05).

In recent years there have been several

changes in FMD control policy (OIE Animal Health Code, 2006; EU Directive 2003/85/EC) to allow emergency vaccination to be more readily considered, particularly under a vaccinate-to-live regime. Given the potential threat that asymptomatic carrier animals pose to vaccination policy and control of the disease in countries where FMD is considered exotic, one fundamental consideration in creating better vaccines is to design them so as to permit reliable differentiation of infected from vaccinated animals. Marker vaccines can comprise many different designs, including learn more so-called negative marker vaccines, characterised by the absence of part, or all, of certain viral proteins [22]. Herpesvirus (glycoprotein gE-deleted pseudorabies virus and bovine herpesvirus) marker vaccines were among the first to be developed and used in the field [23]. These marker vaccines were followed by the development of various genetically modified RNA viruses, such as classical swine fever virus [24] and [25], Newcastle disease virus [26] and [27] and more recently Equine Arteritis virus [28]. To date, the only progress that has been made

in terms of developing FMD marker vaccines which do not rely on the use of NSP as the indicator of infection has been the demonstration of chimeric foot-and-mouth disease vaccines, characterised by the intertypic VP1 G-H loops functioning as the marker KRX-0401 molecular weight [22]. A fundamental aspect of being able to develop marker vaccines, and in particular

negative marker vaccines, is to have a clear understanding of what regions on the virus are necessary for protection in the host and for FMD this is less than clear. There is now a reasonable body of evidence, along with the more recent data showing that the chimeric FMD vaccines could protect cattle against experimental challenge [22], to suggest that the VP1 G-H loop may not be needed for protection. We therefore chose to examine this aspect more closely by studying the immune response generated against a vaccine prepared from a virus lacking a substantial proportion of the VP1 G-H loop, the so-called A− virus, and comparing it to a vaccine prepared from the same virus but containing the complete VP1 G-H Mephenoxalone loop, the A+ virus. Comparison of the A+ and A− viruses through full capsid sequencing, modelling of the predicted structures of each (Fig. 1), serological assessment by VNT (Table 1) and reactivity with a panel of serotype A specific MAbs (Fig. 2) confirmed that the only major difference between the A+ and A− viruses was the VP1 G-H loop. This approach also established that the region of the VP1 G-H loop which remained in the A− virus did not appear to be antigenic and that the deletion had not affected other antigenic sites outside that of the VP1 G-H loop.

Serum glucose was estimated find more by Oxidase method.17 The activities of serum AST and ALT were assayed by Reitman and Frankel method.18 Total cholesterol19 and triglycerides20 were determined by the respective method. Liver was dissected out and washed in normal saline and stored −80 °C for assay of glycogen content by using Anthrone reagent.21 Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by student’s‘t’ test. The values are mean ± SD for six rats in each group. Statistical significance was considered at

p < 0.05. There was a significant elevation of serum glucose, total cholesterol, triglycerides, aspartate transaminase, alanine transaminase while liver glycogen significantly decreased in the diabetic control rats as compared with non-diabetic control group. Table 1 showed the blood glucose levels of the control, Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) at different time points (0, 30, 60, 120, 150 min) after oral administration of glucose (2 g/kg). There was a peak increase in the blood glucose at 30 min in all the groups. In Glibenclamide and 400 mg of MEDH treated group, there was a decrease in blood glucose level at 150 min when compared to control group. Table 2 showed the level of blood Proteasome inhibitor glucose in euglycemic rats at 0, 1, 2 and 4 h of administration. The administration of Glibenclamide (7 mg/kg)

and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) on euglycemic rats was not significant at

1 h, while it was significant at 4 h (p < 0.05) as compared to control. The level of blood glucose in normal and diabetic rats at 0, 1, 2 and 4 h of administration was showed in Table 3. There was a significant elevation of blood glucose level in diabetic group as compared to normal control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) reduced the blood glucose in diabetic rats as compared to control rats. The 4th day treatment with Glibenclamide and 400 mg of MEDH resulted in significant hypoglycemic effect in diabetic group. Table 4 showed the level of serum AST and ALT and liver glycogen in normal and experimental rats. There was a Isotretinoin significant elevation of serum AST and ALT and decrease in liver glycogen content in diabetic control as compared to non-diabetic control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) significantly decreased AST and ALT levels and increased glycogen content in diabetic rats as compared to control rats. There was a significant increase in the cholesterol and triglycerides in diabetic rats as compared to control. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) brought back the levels of cholesterol and triglycerides to near normal rats ( Table 5).

The mentors were responsible for completing a log book for the adolescent with Down syndrome detailing each exercise performed, the weight lifted, the number of repetitions, and number of sets. The control group participants continued with their usual activities, which may have included leisure and sporting activities but did not include a progressive resistance training program. After the trial was

BMN 673 mouse completed, these participants were invited to complete the same program with a student mentor, but no further assessments were conducted. Primary outcome: Muscle strength was assessed using 1 repetition maximum (1RM) force generation tests. These tests established the amount of weight each participant could

lift in a single seated chest press and seated leg press respectively. Single 1RM chest press and leg press tests have high levels of retest reliability (r > 0.89) and demonstrated no systematic change when measured over 3 weeks in adults with neurologic impairment ( Taylor et al 2004). Single 1RM chest press and leg press tests were used as representative measures of upper and lower limb strength, respectively, as they involve the major muscle groups exercising over multiple joints. Secondary outcome: Lower-limb physical function was measured using the Timed Up and Down Stairs test ( Zaino et al 2004). This test was chosen because it is a challenging test of mobility that would be expected to be related to an improved ability to generate muscle force. It has also been implemented previously as an outcome measure in a population

of people with Selleckchem CH5424802 Down syndrome ( Shields et al 2008). Participants were asked to ascend, turn, and descend a flight of stairs as quickly as possible. They could choose any method of traversing the stairs including alternating steps, running up the stairs, or using handrails for support. The time taken to complete the task was recorded in seconds Calpain using a stopwatch. The test was repeated twice and the fastest time was used in the analysis. Secondary analysis of data from our laboratory has demonstrated moderate retest reliability of the Timed Up and Down Stairs test in adults with Down syndrome (ICC3,1 = 0.74). Upper-limb physical function was measured using the Grocery Shelving Task (Hill et al 2004). Participants started from a seated position 2m from a bench. They were asked to stand up and carry 2 grocery bags, each containing 10 items weighing 410 g (total weight of each bag was 4.1 kg), to the bench. The participants then took the items out of the bag and stacked them onto a shelf at shoulder height. The participants completed the task as fast as possible and the time taken was recorded. Participants were given a practice trial before they completed two timed tests, the average of which was used in the analysis.